Douglas Muchmore, MD
La Jolla Endo, LLC, La Jolla, California
Dr. Muchmore is a board certified endocrinologist who practiced tertiary care specialty medicine at Scripps Clinic and Research Foundation for 13 years prior to joining Eli Lilly and Co. where he served as Physician Group Leader for the development of raloxifene hydrochloride for the prevention and treatment of osteoporosis. He then led the clinical development of Lilly’s inhaled insulin program, after which he joined Halozyme Therapeutics as Vice President for Endocrinology Clinical Development in charge of the development of Halozyme’s ultrafast insulin program. Dr. Muchmore has been a consultant to Diasome Pharmaceuticals since the beginning of 2017, now serving as Chief Technology Officer. Dr. Muchmore is a graduate of Stanford University and University of California, San Diego School of Medicine. He served as intern and resident in internal medicine at the University of Washington, Seattle and then as fellow in endocrinology and metabolism at University of Washington Hospital, Seattle.